Lung Cancer - 29/03/15

Doi : 10.1016/j.cpet.2014.12.002

Tim Akhurst, MD, FRACP ^a,^b,^⁎ , Michael MacManus, MD, FRANZCR ^b,^c, Rodney J. Hicks, MD, FRACP ^a,^b
^a Division of Radiation Oncology and Cancer Imaging, Centre for Molecular Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
^b The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
^c Division of Radiation Oncology and Cancer Imaging, Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia

^∗Corresponding author. Centre for Molecular Imaging, Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne, Victoria 3002, Australia.

Résumé

¹⁸F-fluorodeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) plays a key role in the evaluation of undiagnosed lung nodules, when primary lung cancer is strongly suspected, or when it has already been diagnosed by other techniques. Although technical factors may compromise characterization of small or highly mobile lesions, lesions without apparent FDG uptake can generally be safely observed, whereas FDG-avid lung nodules almost always need further evaluation. FDG-PET/CT is now the primary staging imaging modality for patients with lung cancer who are being considered for curative therapy with either surgery or definitive radiation therapy.

Le texte complet de cet article est disponible en PDF.

Keywords : Positron emission tomography, Lung cancer, Radiotherapy, Chemotherapy, CT scanning